Company: SCLXW
Filing Date: 2025-05-07
Form Type: POS AM
Source: 0001193125-25-115088
Chunk: 188

Company: Scilex Holding Co
Filing Date: 2025-05-07
Form: POS AM
Chunk 188
---
 agreement dated as of March 21, 2023 and amended on October 11, 2023, between Yorkville and us, (ii) the Oramed Note, (iii) the non-refundable deposit in the aggregate principal amount of $10.0 million (the “FSF Deposit”) pursuant to the Commitment Letter dated as of June 11, 2024, entered into with FSF, (iv) the Tranche B Notes issued in October 2024 in the principal amount of $50.0 million and (v) the purchased revenue liability associated with the ZTlido Royalty Purchase Agreement with certain institutional investors (collectively, the “ZTlido Royalty Investors”) and Oramed. See Note 4 titled “Fair Value Measurements” to our consolidated financial statements appearing elsewhere in this prospectus.

Interest Expense, Net

Interest expense, net consists of interest related to the loans in an aggregate principal amount of up to $30.0 million (the “Revolving Facility”) made available by eCapital Healthcare Corp. pursuant to a Credit and Security Agreement (the “eCapital Credit Agreement”) that Scilex Pharma entered into on June 27, 2023.

Loss on Foreign Currency Exchange

Loss on foreign currency exchange relates to foreign exchange losses on payments made to our foreign supplier, Itochu, a manufacturer and supplier of lidocaine tape products, including ZTlido and SP-103.**

<div align='center'>117</div>

Results of Operations The following tables summarize our results of operations for the years ended December 31, 2024 and 2023 (in thousands):

|                                                        |     | Year Ended December 31, |    2024 |   |     |   |     2023 |   |     |   | Changes |   |
|:-------------------------------------------------------|:----|:------------------------|--------:|:--|:----|:--|---------:|:--|:----|:--|--------:|:--|
| Statements of Operations Data:                         |     |                         |         |   |     |   |          |   |     |   |         |   |
| Net revenue                                            |     | $                       |  56,590 |   |     | $ |   46,743 |   |     | $ |   9,847 |   |
| Net operating costs and expenses:                      |     |                         |         |   |